

Edition: BP 2025 (Ph. Eur. 11.6 update)

Xylometazoline Nasal Drops

[General Notices](#)

Action and use

Alpha-adrenoceptor agonist.

DEFINITION

Xylometazoline Nasal Drops are a solution of Xylometazoline Hydrochloride in Purified Water.

The nasal drops comply with the requirements stated under Nasal Preparations and with the following requirements.

Content of xylometazoline hydrochloride, $C_{16}H_{24}N_2 \cdot HCl$

90.0 to 110.0% of the stated amount.

IDENTIFICATION

A. To a volume of the nasal drops containing 50 mg of Xylometazoline Hydrochloride add 5 mL of 1M [sodium hydroxide](#), extract with 10 mL of [dichloromethane IR](#), evaporate to dryness and dissolve the residue in 0.5 mL of [dichloromethane IR](#). The [infrared absorption spectrum](#) of the resulting solution, [Appendix II A](#), is concordant with the *reference spectrum* of xylometazoline ([RS 362](#)).

B. To a volume containing 0.5 mg of Xylometazoline Hydrochloride add 0.2 mL of a 5% w/v solution of [sodium nitroprusside](#) and 0.1 mL of 5M [sodium hydroxide](#) and allow to stand for 10 minutes. Add 1 mL of a 10% w/v solution of [sodium hydrogen carbonate](#). A violet colour is produced.

TESTS

Acidity

pH, 5.6 to 6.6, [Appendix V L](#).

N-(2-Aminoethyl)-4-*tert*-butyl-2,6-xylylacetamide

Carry out the method for [thin-layer chromatography](#), [Appendix III A](#), using [silica gel HF₂₅₄](#) as the coating substance and a mixture of 200 volumes of [methanol](#) and 3 volumes of 13.5M [ammonia](#) as the mobile phase. Apply separately to the plate 5 µL of each of the following solutions. For solution (1) add a volume of the nasal drops containing 10 mg of Xylometazoline Hydrochloride to 30 mL of [water](#), add 5 mL of 5M [sodium hydroxide](#), mix, extract with three 20 mL quantities of [dichloromethane](#), evaporate the combined extracts to dryness and dissolve the residue in 1 mL of [dichloromethane](#). Solution (2) contains 0.03% w/v of [xylometazoline impurity A EPCRS](#) in [dichloromethane](#). After removal of the plate, allow it to dry in air and spray with a solution prepared by dissolving 0.3 g of [ninhydrin](#) in a mixture of 100 mL of [butan-1-ol](#) and 3 mL of [glacial acetic acid](#). Heat at 100° for 10 minutes, allow to cool, and spray with [dilute potassium iodobismuthate solution](#). Any spot corresponding to xylometazoline impurity A [*N*-(2-aminoethyl)-4-*tert*-butyl-2,6-

xylylacetamide] in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (2).

ASSAY

To a volume of the nasal drops containing 10 mg of Xylometazoline Hydrochloride add 5 mL of [water](#), 10 mL of [2M hydrochloric acid](#) and 10 mL of [dichloromethane](#) and shake for 1 minute. Discard the dichloromethane layer and repeat the extraction with two further 10 mL quantities of [dichloromethane](#). Add to the aqueous extract 10 mL of 5M [sodium hydroxide](#) and 10 mL of [dichloromethane](#), shake for 1 minute and allow to separate. Filter the dichloromethane extract through glass wool and repeat the extraction with four further 10 mL quantities of [dichloromethane](#). Evaporate the combined dichloromethane extracts almost to dryness on a water bath, removing the final traces of solvent in a current of air, and dissolve the residue in 10 mL of 0.01M [hydrochloric acid](#). To 2 mL of this solution add 3 mL of [water](#), 2.5 mL of 1M [sodium hydroxide](#) and 2.5 mL of a 5% w/v solution of [sodium nitroprusside](#), mix and allow to stand protected from light for 10 minutes. Add 10 mL of a freshly prepared 8.3% w/v solution of [sodium hydrogen carbonate](#), dilute to 100 mL with [water](#), allow to stand protected from light for 10 minutes and measure the [absorbance](#) of the resulting solution at the maximum at 560 nm, [Appendix II B](#), using in the reference cell a solution prepared by treating 5 mL of [water](#) and 2.5 mL of 1M [sodium hydroxide](#) in the same manner, beginning at the words 'and 2.5 mL of a 5% w/v solution of [sodium nitroprusside](#) ...'. Repeat the operation using a 0.1% w/v solution of [xylometazoline hydrochloride BPCRS](#), diluted if necessary with [water](#), in place of the nasal drops. Calculate the content of $C_{16}H_{24}N_2 \cdot HCl$ in the nasal drops from the absorbances obtained using the declared content of $C_{16}H_{24}N_2 \cdot HCl$ in [xylometazoline hydrochloride BPCRS](#).

STORAGE

Xylometazoline Nasal Drops should be protected from light.